Predictive Oncology Inc. (POAI) - מכפיל EV/EBITDA
Predictive Oncology (POAI) demonstrates resilience to market volatility, driven by demand for advanced medtech and the success of clinical trials. This chart confirms the market price, where the EV/EBITDA multiple stands at 0.00, helping to track these trends. The company is implementing sustainable AI solutions to combat cancer, thereby reducing laboratory waste. Management is betting on global alliances with pharma behemoths to monetize its digital platforms.
פילוחים אנליטיים של חברת predictive-oncology.com (POAI)
The EV/EBITDA multiple compares the total enterprise value of a business with its operating profit before interest and taxes, allowing for the determination of an asset's undervaluation regardless of its capital structure. By analyzing the dynamic EV/EBITDA value of Predictive Oncology (POAI), an investor can assess the cost management efficiency of Predictive Oncology (POAI) amid its dependence on the R&D budgets of pharma behemoths and the demand for its AI platforms.
